---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-006039"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T14:50:28.534344+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ardelyx reports FY2022 net loss $67.2M; IBSRELA sales $15.6M; XPHOZAH NDA resubmission expected early Q2 2023

## Summary
- Net loss for FY2022 was $67.2M ($0.42/share) vs $158.2M ($1.52/share) in 2021.
- IBSRELA net product sales $15.6M for FY2022, with $8.7M in Q4; consistent prescription growth.
- Cash and investments $123.9M at Dec 31, 2022; $121.0M at Feb 28, 2023 (includes $20M ATM proceeds).
- XPHOZAH NDA resubmission on track for early Q2 2023 after productive FDA Type A meeting.
- Debt facility amended: interest-only period may extend to Mar 2025; additional $22.5M available contingent on FDA approval and revenue targets.

## SEC filing metadata
- accession: 0001628280-23-006039
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/0001628280-23-006039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/ardx-20230302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-006039
- JSON: https://secwatch.observer/filing/0001628280-23-006039.json
- Plain text: https://secwatch.observer/filing/0001628280-23-006039.txt

## Key facts
- Earnings Releases
  ARDELYX, INC. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales
  evidence_url: https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/0001628280-23-006039-index.htm
- Earnings Releases
  ARDELYX, INC. reported financial results for fourth quarter and full year ended December 31, 2022.
  - Period: fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: Full Year 2022 Financial Results • Cash Position: As of December 31, 2022, the company had total cash, cash equivalents and short-term investments of $123.9 million, as compared to total cash, cash equivalents and short-term investments of $116.7 million as of December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/0001628280-23-006039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.